- Home
- OTLK vs VGI Comparison
OTLK vs VGI Comparison
Compare OTLK & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | VGI |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 90.1M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | VGI |
|---|---|---|
| Price | $2.18 | $7.72 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 46.0K |
| Earning Date | 12-24-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,505,322.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $342.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $6.68 |
| 52 Week High | $3.39 | $7.99 |
Technical Indicators
Market Signals| Indicator | OTLK | VGI |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 39.72 |
| Support Level | $1.91 | $7.79 |
| Resistance Level | $2.10 | $7.86 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 95.65 | 7.87 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.